Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Jiangsu Hengrui to Return Telomelysin’s China Rights to Oncolys
June 10, 2020
- Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe
June 9, 2020
- Evrenzo Shows Non-Inferiority to Nesp in Non-Dialysis CKD Patients
June 9, 2020
- Takhzyro Shows Sustained Effect in Staving Off HAE Attacks
June 9, 2020
- Big 3 Generic Firms Log 5.9% Sales Increase in FY2019, with Contraction in Overseas Business: Jiho Tally
June 9, 2020
- Bayer HIF-PH Inhibitor Molidustat Filed in Japan in Q1
June 9, 2020
- Japan Team to Develop Nafamostat Inhaler Formulation for COVID-19
June 9, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Chugai Files FoundationOne as Lynparza CDx for mCRPC
June 8, 2020
- Meiji Pharma Jettisons Nail Ringworm Med ME1111
June 8, 2020
- Opdivo Gets Taiwan Nod for Second-Line Esophageal Cancer
June 8, 2020
- Ono Kicks Off Japan Clinical Study for Pancreatitis Med Foipan for COVID-19
June 8, 2020
- Rakuten Medical, MD Anderson Pair Up on Cancer Photoimmunotherapy
June 8, 2020
- Eylea Pre-Filled Syringe Now Available in Japan: Bayer, Santen
June 8, 2020
- Nipro Launches Stemirac Manufacturing Facility in Tokyo
June 8, 2020
- Latuda to Finally Hit Japan Market on June 11
June 5, 2020
- Opdivo Top-Selling Drug in May, Keytruda Falls to Second: Encise
June 5, 2020
- Kyowa Kirin Looks to Make Crysvita 1st In-House Blockbuster, Sees 100 Billion Yen Target “Not Unachievable”
June 5, 2020
- Humira Remains Global Top-Seller in 2019
June 4, 2020
- Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs
June 3, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…